Catherine Anastasopoulou, MD
Endocrinology, Diabetes & Metabolism · Elkins Park, PANPI 1225099120
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 54 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 44.9% of the total.
Across 562 payments — averaging $53.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$14K
- Ascendis Pharma Endocrinology Inc$5K
- Amgen$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Radius Health, Inc.$964
- plus $6K from 48 others
Across 52 payments — averaging $1513.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diagnostics Operations, Inc.$51K
- Ascendis Pharma Endocrinology Inc$20K
- F. Hoffmann-la Roche AG$7K
What the payments were for
- Consulting fees$7,38825%
- Speaking & faculty fees$8,82629%
- Travel & lodging$5992%
- Food & beverage$12,98843%
- Education$2251%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$8,123
- Yorvipath$4,956
- FreeStyle Lite system$200
- TOUJEO$126
- MINIMED 780G$125
- RYBELSUS$123
- Tymlos$120
- SOLIQUA 100/33$103
- SKYTROFA$100
How this compares
$30,086 in reported general payments places this provider in the 85th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 186 | $287,327 |
| TrulicityDulaglutide | 115 | $150,447 |
| JardianceEmpagliflozin | 128 | $148,953 |
| ProliaDenosumab | 78 | $122,481 |
| Teriparatide | 57 | $117,935 |
| TymlosAbaloparatide | 20 | $52,039 |
| MounjaroTirzepatide | 38 | $40,489 |
| FarxigaDapagliflozin Propanediol | 25 | $29,634 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 12 | $28,462 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $27,256 |
| TradjentaLinagliptin | 23 | $26,348 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $25,955 |
| VascepaIcosapent Ethyl | 22 | $18,289 |
| Novolog FlexpenInsulin Aspart | 44 | $14,587 |
| Cinacalcet Hcl | 55 | $13,770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,373 | $287,327186 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,194 | $190,936153 claims |
| Boehringer IngelheimJardiance, Tradjenta | $405 | $175,301151 claims |
| AmgenProlia, Evenity (2 Syringes) | $1,387 | $150,94390 claims |
| Radius Health, Inc.Tymlos | $964 | $52,03920 claims |
| AstraZenecaFarxiga | $392 | $29,63425 claims |
| MerckJanumet Xr | $259 | $6,00211 claims |
| AbbVieSynthroid | $24 | $4,22451 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Elkins Park
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
- Mitchell LazarPhiladelphia$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.